

THE WISTAR INSTITUTE

CAMB/IMM 609: Vaccines & Immune Therapy Fall 2019

Time: 3:00 PM – 5:00 PM Location: Grossman Auditorium 1st Floor The Wistar Institute 3601 Spruce Street Instructors: David Weiner, Paul Offit, Stanley Plotkin Class Coordinator: Jeneice Hubert

<u>Date</u>	Title	<u>Lecturer</u>
Sept 19	Welcome/Vaccine History	David Weiner – Wistar
Sept 25	Cellular Immune Responses	Michael Betts - PENN
Sept 26	the Hemophilus influenza type B Vaccine: A Scientific Biography	William Egan - GSK
Oct 2	B Cells, Antibodies, & Humoral Immune Response	David Allman – PENN
Oct 3	Structure-based vaccine design	Daniel Kulp - Wistar
Oct 9	Yom Kippur	NO CLASS
Oct 10	Rotavirus Vaccines	Paul Offit - CHOP
	Correlates of Protection by Vaccines	Stanley Plotkin – Emeritus Professor of Pediatrics
Oct 16	Progress Towards the Development of A Prophylactic Vaccine for HCMV	Amy Espeseth – Merck
	Adoptive Cell Therapy for Cancer	Marco Ruella – UPENN

P (215) 898-0381 E jhubert@wistar.org

VACCINE & Immunotherapy Center

THE WISTAR INSTITUTE

Date	Title	Lecturer_
Oct 17	TBD TBD	Tonya Villafana – MedImmune Mark Esser - MedImmune
Oct 23	TBD	Matthew Morrow - Inovio
Oct 24	Cure-HIV	Luis Montaner - Wistar
Oct 30 Are we addr	Vaccine Development for Emerging Infectious Diseases: ressing lessons learned from the Ebola outbrea	Swati Gupta - IAVI ks?
	Responding to the Zika epidemic Through rapid development of vaccines	Jon Heinrichs – Sanofi Pasteur
Oct 31	The Challenge of Successful Vaccines Development & Delivery	Emilio Emini – Bill & Melinda Gates Foundation
Nov 6	OPEN	
Nov 7	Vaccines for Infectious Diseases that Disproportionately Impact the Poor	Penny Heaton – Bill and Melinda Gates Medical Research Institution
Nov 13	Vaccine Safety	Paul Offit - CHOP
Nov 14	Considerations in developing a Vaccine to protect against neonatal group B Streptococcal infection	Kathrin Jansen – Pfizer

THE WISTAR INSTITUTE

VACCINE & Immunotherapy Center

Date	<u>Title</u>	<u>Lecturer</u>
Nov 20	Developing vaccines against emerging infections outside of the usual regulatory framework	Gary Kobinger – PHA Canada
Nov 21	Regulatory Considerations for Preventative Vaccines	Doran Fink – FDA
	Understanding Vaccine Safety After Licensure	Meghna Alimchandani - FDA
Nov 27	THANKSGIVING	NO CLASS
Nov 28	THANKSGIVING	NO CLASS
Dec 4	Meningococcal Vaccines	Nicole Brown - CDC
	Personalized Cancer Vaccines	Gerald Linette – UPENN
Dec 5	Pneumococcal Conjugate	William Gruber – Pfizer
2000		
Dec 11	Vaccine Confidence-Fact, Fiction, Perception	Ruxandra Draghia - Merck
Dec 12	EXAMS	